CJC-1295 (without DAC) vs Vesugen
Well Studied vs Moderate Research
synergistic Mechanism-based · 47% CJC-1295 (without DAC) and Vesugen work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.
Molecular Data
CJC-1295 (without DAC) Vesugen
Weight 3,367.97 Da 390 Da
Half-life 30 minutes - 2 hours Not established
Chain 30 amino acids 3 amino acids
Type GHRH analog Tripeptide bioregulator
Key Benefits
CJC-1295 (without DAC)
01 Preserves natural GH pulsatility
02 Minimal side effects
03 No receptor desensitization
04 Precise GH release control
05 4x greater receptor affinity than native GHRH
Vesugen
01 Protects vascular system from aging effects
02 Limits atherosclerosis development
03 Decreases endothelial cell dysfunction
04 Activates SIRT1 anti-aging pathway
05 Enhances stem cell proliferation
06 Reduces cellular senescence markers
07 Reverses SASP phenotype
08 Works synergistically with Cardiogen
Dosing Protocols
CJC-1295 (without DAC)
100-300mcg per injection / 2-3 times daily (morning, post-workout optional, bedtime)
Anti-Aging/Wellness 100mcg 2x daily (morning and bedtime)
Body Composition 100-150mcg 3x daily (morning, post-workout, bedtime)
Maximum GH Release 200mcg 2-3x daily with GHRP
Sleep Enhancement 100-200mcg Once at bedtime
Vesugen
10-20 mg per day (oral capsules) or 10 mg (injectable) / Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
Research protocol 10 mg Daily for 10 days
Side Effects
CJC-1295 (without DAC)
Generally well-tolerated at recommended doses
Temporary facial flushing/warmth (5-10 minutes post-injection)
Vesugen
Generally well-tolerated
Minimal side effects reported
Contraindications
Active cancer (due to growth-promoting effects)
Diabetic retinopathy
Severe kidney disease
Pregnancy or breastfeeding
Active cardiovascular emergencies (seek medical care)
Known hypersensitivity
Pregnancy or breastfeeding
Research Evidence
CJC-1295 (without DAC) Vesugen
Status Well Studied Moderate Research
References 5 studies 3 studies
Latest November 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.